Skip to main content

Table 1 Studies evaluating several treatment regimens of RT on patients with low-, intermediate- and high-risk PCa

From: Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

Author, year Ref RT type n total dose (Gy) total fractions Gy/ fraction PFS def. Risk group n 5-year PFS (%)
LR IR HR LR IR HR
Kuban, 2008 [6] 3D 151 78 39 2 P 30 68 53 100 86 69
3D 150 70 35 2 P 31 71 48 88 83 54
Al-Mamgani, 2008 [7] 3D 333 78 39 2 P 63 90 180 N/A 70 N/A
3D 331 68 34 2 P 56 89 185 N/A 60 N/A
Zietman, 2010 [8] 3D 195 79 44 1.8 P 116 72 7 95 79 N/A
3D 197 70 39 1.8 P 111 76 10 75 68 N/A
Dearnaley, 2007 [9] 3D 422 74 37 2 P 99 127 184 71 71 N/A
3D 421 64 32 2 P 95 137 175 60 60 N/A
Michalski, 2010, 2012 [10, 11] 3D 108 68 38 1.8 P 55 37 69 68 70 42
3D 300 74 41 1.8 P 91 75 39 73 62 62
3D 167 79 44 1.8 P 85 54 36 67 70 70
3D 256 74 37 2 P 92 109 40 84 74 54
3D 220 78 39 2 P 80 109 32 80 69 67
Beckendorf, 2011 [12] 3D 153 70 35 2 P 153 68
3D 153 80 40 2 P 153 74
Michalski, 2014 [13] 3D+ IMRT 748 79 44 1.8 P 748 75
3D+ IMRT 751 70 39 1.8 P 751 60
3D (491) N/A N/A N/A P 30 68 53 N/A N/A N/A
IMRT (257) N/A N/A N/A P 31 71 48 N/A N/A N/A
Lukka, 2005 [14] 3D 470 66 33 2 A 470 N/A 53 N/A
3D 466 52 20 2.63 A 466 N/A 60 N/A
Yeoh, 2011 [15] 3D 109 64 32 2 P 109 N/A 58 N/A
3D 108 55 20 2.75 P 108 N/A 69 N/A
Arcangeli, 2012 [16] 3D 85 80 40 2 P 85 N/A N/A 79
3D 83 62 20 3.1 P 83 N/A N/A 85
Pollack, 2013 [17] IMRT 152 76 38 2 P 101 51 N/A 86 86
IMRT 151 70 26 2.7 P 98 53 N/A 86 86
Kuban, 2010 [18] IMRT 102 76 42 1.8 P 30 1 1 96 96 N/A
IMRT 102 72 30 2.4 P 30 1 1 97 97 N/A
Mantz, 2014 [19] Gantry 102 40 5 8.0 P 40 100 N/A N/A
Katz, 2010, 2011 [20, 21] RA 304 35 5 7.0 P 211 81 12 99 93 75
36 5 7.3 P
Fuller, 2014 [22] RA 60 38 4 9.5 P 40 39 100 92 N/A
Dubray, 2016 [23] 3D without ADT 191 80 40 2 191 76
with ADT 179 179 84
Dong, 2017 [24] 3D/IMRT without ADT 979 74–80 or 70.2 40 or 26 1.8–2.7 979 87.3
with ADT 155 155 84
  1. 3D-CRT 3 dimensional conformal radiation therapy, PFS progression-free survival, HR high risk, IMRT intensity modulated radiation therapy, IR intermediate risk, LR low risk, N/A not applicable. The definition of PFS (Phoenix, P; or ASTRO A) is listed